GFAP and dementia: GFAP-immunoreactive astrocytes are reduced in concert with alterations in CLDN5 protein levels and organization (Camire et al., 2015; Sántha et al., 2015) and GFAP levels are relevant to dementia risk (Kim et al., 2023; Gonzales et al., 2022).